TricValve Transcatheter Bicaval Valve System for Severe Tricuspid Insufficiency: Events at One Year

TricValve is the first bicaval valve system to obtain CE-Mark approval. This device heterotopic device eliminates tricuspid insufficiency reflux into the venous system, reducing peripheral congestion. It represents a unique option for patients at high surgical risk who make poor candidates for replacement or repair. 

COMPARE TAVI: Resultados al año de un estudio aleatorizado que compara dos válvulas balón expandibles

However, its long term duration, efficacy and safety remain unknown. The TRICUS EURO (n=35) showed TricValve improved functional class and quality of life at 6 months and one year (delta QoL 29.1). 

This was a multicenter registry initiated by researchers including patients from 27 hospitals, with torrential TI, refractory right failure and inoperable, with adequate bicaval anatomy. 

Mean age was 77.8 ±7.5 years, 65.2% were women, 50% had a history of heart surgery, 19% transcatheter valve intervention, 34.2% PPM or ICD, mean STS was 9.5±7.9. Mortality prediction according to TRI-SCORE was intermediate in 36.8% and high in 45.6%. 

Intraprocedural success reached 96.1% of cases, there was 2.9% of inferior vena cava malapposition requiring a new valve, in-hospital mortality was 8.3%, there was 5.39% of access complications and 3.9% of cardiac complications, 47.1% reported shoulder pain, and mean hospital stay was 8 days.  

Read also: Long Term Results of the International Chimney Registry.

In-hospital mortality predictors were functional class IV (OR 4.36, P=0.049), creatinine ≥1.5mg/dl (OR 3.62; p=0.030), increased GGT and TAPSE ≤12mm (6.92; p=0.025). As regards clinical events at one year, there was improved functional class (19.8% FC II baseline 81.5% FC I-II at one year) and reduced signs of right failure (reduced edema from 73% to 22% and ascites from 31.2% to 4.9%; p≤0.001). 

There was an important reduction of hospitalization for cardiac failure (IRR 0.44, IC95% 0.29-0.66; p≤0.001).

Presented by Angel Sanchez Recalde at Top Late-Breaking Trials, PCR London Valves, November 24, 2024, London, GB.


Subscreva-se a nossa newsletter semanal

Receba resumos com os últimos artigos científicos

Dr. Omar Tupayachi
Dr. Omar Tupayachi
Member of the Editorial Board of solaci.org

More articles by this author

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

Prospective Analysis of the Feasibility of the PASCAL System for Transcatheter Mitral Repair: OneForAll Registry

Courtesy of Dr. Juan Manuel Pérez. Mitral transcatheter edge-to-edge repair (M-TEER) is an effective option for patients with severe mitral regurgitation who are at high...

Left Bundle Branch Block after TAVR: What Is Its Impact?

Courtesy of Dr. Juan Manuel Pérez. Left bundle branch block (LBBB) is a common complication following transcatheter aortic valve replacement (TAVR), which can be either...

Multicenter Experience with 3D Intracardiac Echocardiography for Guiding Interventional Cardiac Procedures

Courtesy of Dr. Juan Manuel Pérez. Imaging techniques play a fundamental role in interventional cardiac procedures. Intracardiac echocardiography (ICE) appears as an alternative to transesophageal...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...